{"title":"Endothelial cell-modified BMSC-GT/PCL nanofiber membrane sheet constructs promote bone tissue regeneration.","authors":"Qian Zhou, Mengnan Wen, Yiwu Zhang, Zhinan Wang, Guangdong Zhou, Xiaoqin Liang","doi":"10.3389/fbioe.2025.1557279","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Bone defect repair remains a major challenge in modern medicine. Although bone marrow mesenchymal stem cells (BMSCs) possess multilineage differentiation potential, traditional BMSC constructs are often limited in clinical applications due to insufficient osteogenic differentiation efficiency and inadequate vascularization.</p><p><strong>Methods: </strong>This study developed an innovative bone tissue engineering strategy by combining BMSCs with gelatin/polycaprolactone (GT/PCL) nanofiber membranes to form cell sheets, which were then modified with endothelial cells (ECs) on the surface. The sheets were subsequently rolled into three-dimensional scaffolds to systematically evaluate their osteogenic potential and underlying mechanisms.</p><p><strong>Resuilts: </strong>Results showed that electrospun GT/PCL nanofiber membranes exhibited uniform fiber structure (diameter 200-500 nm), successfully mimicking the microstructure of natural extracellular matrix. <i>In vitro</i> experiments demonstrated that after 14 days of culture, EC modification significantly enhanced the osteogenic differentiation of BMSCs compared to unmodified controls, with approximately 3-fold increase in <i>ALP</i> expression (p < 0.05) and 2.5-fold increase in angiogenic factor <i>VEGF</i> expression (p < 0.01). Subcutaneous implantation in nude mice revealed superior bone formation capability of EC-modified constructs at both 4 and 8 weeks: micro-CT analysis showed bone density reaching 350 mg/cm<sup>3</sup>, bone surface area approaching 400 mm<sup>2</sup>, and bone volume fraction of approximately 20%, significantly higher than control groups (p < 0.0001). Immunohistochemical evaluation further confirmed more mature trabecular bone structure and richer vascular networks in EC-modified groups.</p><p><strong>Discussion: </strong>Mechanistic studies revealed that EC modification promoted bone regeneration through three key pathways: optimization of local vascular microenvironment for improved nutrient supply, activation of intercellular synergistic signaling pathways, and reconstruction of physiological bone tissue microenvironment. This study not only validates the application value of this composite strategy in bone tissue engineering but also provides important theoretical basis for developing novel bone regeneration solutions.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1557279"},"PeriodicalIF":4.3000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906688/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1557279","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Bone defect repair remains a major challenge in modern medicine. Although bone marrow mesenchymal stem cells (BMSCs) possess multilineage differentiation potential, traditional BMSC constructs are often limited in clinical applications due to insufficient osteogenic differentiation efficiency and inadequate vascularization.
Methods: This study developed an innovative bone tissue engineering strategy by combining BMSCs with gelatin/polycaprolactone (GT/PCL) nanofiber membranes to form cell sheets, which were then modified with endothelial cells (ECs) on the surface. The sheets were subsequently rolled into three-dimensional scaffolds to systematically evaluate their osteogenic potential and underlying mechanisms.
Resuilts: Results showed that electrospun GT/PCL nanofiber membranes exhibited uniform fiber structure (diameter 200-500 nm), successfully mimicking the microstructure of natural extracellular matrix. In vitro experiments demonstrated that after 14 days of culture, EC modification significantly enhanced the osteogenic differentiation of BMSCs compared to unmodified controls, with approximately 3-fold increase in ALP expression (p < 0.05) and 2.5-fold increase in angiogenic factor VEGF expression (p < 0.01). Subcutaneous implantation in nude mice revealed superior bone formation capability of EC-modified constructs at both 4 and 8 weeks: micro-CT analysis showed bone density reaching 350 mg/cm3, bone surface area approaching 400 mm2, and bone volume fraction of approximately 20%, significantly higher than control groups (p < 0.0001). Immunohistochemical evaluation further confirmed more mature trabecular bone structure and richer vascular networks in EC-modified groups.
Discussion: Mechanistic studies revealed that EC modification promoted bone regeneration through three key pathways: optimization of local vascular microenvironment for improved nutrient supply, activation of intercellular synergistic signaling pathways, and reconstruction of physiological bone tissue microenvironment. This study not only validates the application value of this composite strategy in bone tissue engineering but also provides important theoretical basis for developing novel bone regeneration solutions.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.